SL-401
Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 72 patients (estimated)
- Sponsors
- Dana-Farber Cancer Institute
- Collaborators
- Stemline Therapeutics, Inc.
- Tags
- Antimetabolites, BCL-2 Inhibitor, Hypomethylating Agents (HMA), CD123
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1536
- NCT Identifier
- NCT03113643
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.